Safety and Efficacy of Concomitant Erenumab and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients

Presented at the AAN Annual Meeting, April 22-27, 2023 Authors: Zubair Ahmed, Robert Vann, Christopher Fitzpatrick, Sutapa Ray, Stephen Shrewsbury, Sheena Aurora Objective: To report safety and efficacy in migraine patients who concomitantly used erenumab and INP104 over 24 weeks. Background: Breakthrough migraine attacks can occur while a patient is on preventive therapy; therefore, effective acute medications that can be used concomitantly […] The post Safety and Efficacy of Concomitant Erenumab and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients appeared first on Impel Pharm